ÂÜÀòÂÒÂ×

Mark Ragains is currently a scientist at Turn Biotechnologies, where they focus on formulation. Mark has over fifteen years of experience in the field, having worked at Genentech, Alcon, and Amgen.

Mark began their career in 2005 as a senior scientist at Amgen. Mark worked there for six years before moving to Alcon in 2011. At Alcon, they were promoted to associate director after just three years. Mark worked at Alcon for three years before returning to Genentech in 2015.

At Genentech, Mark focused on preformulation of small-molecules for API's targeting oral or intravenous delivery in the clinic. Mark also supported CMC activities including tech transfer, batch record review, and authoring relevant sections of IMPD. Mark was successful in submitting and approving a CTA. In 2020, they moved to Turn Biotechnologies, where they continue to work on formulation.

Mark Ragains earned their Doctor of Philosophy in Physical Organic Chemistry from the University of California, Santa Cruz.

Mark Ragains (C) reports to TBH, Head of Formulations.